Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Colorectal Neoplasms 2Wilms Tumor 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms 1Liver Neoplasms 1Hepatoblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colonic Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Sorafenib 68Bevacizumab 44Oxaliplatin 25Doxorubicin 22Gemcitabine 21Fluorouracil 21Radiosurgery 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17lenvatinib 17Cisplatin 17Capecitabine 17atezolizumab 14Leucovorin 14Hepatectomy 14Radiotherapy 12tremelimumab 10Irinotecan 10Drug Therapy 10Cyclophosphamide 10Carboplatin 10Blood Specimen Collection 10Ipilimumab 9regorafenib 8Liver Transplantation 8Everolimus 8Cryosurgery 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × cixutumumab × Gastrointestinal × Clear all
NCT00906373 2018-06-04

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

Eli Lilly and Company

Phase 2 Completed
47 enrolled 14 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡